These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 32067281)

  • 41. Personalized maps of T1 relaxometry abnormalities provide correlates of disability in multiple sclerosis patients.
    Chen X; Schädelin S; Lu PJ; Ocampo-Pineda M; Weigel M; Barakovic M; Ruberte E; Cagol A; Marechal B; Kober T; Kuhle J; Kappos L; Melie-Garcia L; Granziera C
    Neuroimage Clin; 2023; 37():103349. PubMed ID: 36801600
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cerebrospinal Fluid-In Gradient of Cortical and Deep Gray Matter Damage in Multiple Sclerosis.
    Rubin M; Pagani E; Preziosa P; Meani A; Storelli L; Margoni M; Filippi M; Rocca MA
    Neurol Neuroimmunol Neuroinflamm; 2024 Jul; 11(4):e200271. PubMed ID: 38896808
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Contribution of cortical and white matter lesions to cognitive impairment in multiple sclerosis.
    Papadopoulou A; Müller-Lenke N; Naegelin Y; Kalt G; Bendfeldt K; Kuster P; Stoecklin M; Gass A; Sprenger T; Radue EW; Kappos L; Penner IK
    Mult Scler; 2013 Sep; 19(10):1290-6. PubMed ID: 23459568
    [TBL] [Abstract][Full Text] [Related]  

  • 44. 7 T imaging reveals a gradient in spinal cord lesion distribution in multiple sclerosis.
    Ouellette R; Treaba CA; Granberg T; Herranz E; Barletta V; Mehndiratta A; De Leener B; Tauhid S; Yousuf F; Dupont SM; Klawiter EC; Sloane JA; Bakshi R; Cohen-Adad J; Mainero C
    Brain; 2020 Oct; 143(10):2973-2987. PubMed ID: 32935834
    [TBL] [Abstract][Full Text] [Related]  

  • 45. MRI phenotypes based on cerebral lesions and atrophy in patients with multiple sclerosis.
    Tauhid S; Neema M; Healy BC; Weiner HL; Bakshi R
    J Neurol Sci; 2014 Nov; 346(1-2):250-4. PubMed ID: 25220114
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The role of endogenous antiradical protective system in multiple sclerosis.
    Davitashvili D; Beridze M; Shakarishvili R; Kiziria M; Sanikidze T
    Georgian Med News; 2012 Apr; (205):11-9. PubMed ID: 22665726
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Evolution of retinal degeneration and prediction of disease activity in relapsing and progressive multiple sclerosis.
    Krämer J; Balloff C; Weise M; Koska V; Uthmeier Y; Esderts I; Nguyen-Minh M; Zimmerhof M; Hartmann A; Dietrich M; Ingwersen J; Lee JI; Havla J; Kümpfel T; Kerschensteiner M; Häußler V; Heesen C; Stellmann JP; Zimmermann HG; Oertel FC; Ringelstein M; Brandt AU; Paul F; Aktas O; Hartung HP; Wiendl H; Meuth SG; Albrecht P
    Nat Commun; 2024 Jun; 15(1):5243. PubMed ID: 38897994
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cortical surface thickness, subcortical volumes and disability between races in relapsing-remitting multiple sclerosis.
    Bross M; Hackett M; Bernitsas MM; Bao F; Carla-Santiago-Martinez ; Bernitsas E
    Mult Scler Relat Disord; 2021 Aug; 53():103025. PubMed ID: 34052742
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A reassessment of the plateauing relationship between T2 lesion load and disability in MS.
    Sormani MP; Rovaris M; Comi G; Filippi M
    Neurology; 2009 Nov; 73(19):1538-42. PubMed ID: 19794123
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Neuroinflammatory component of gray matter pathology in multiple sclerosis.
    Herranz E; Giannì C; Louapre C; Treaba CA; Govindarajan ST; Ouellette R; Loggia ML; Sloane JA; Madigan N; Izquierdo-Garcia D; Ward N; Mangeat G; Granberg T; Klawiter EC; Catana C; Hooker JM; Taylor N; Ionete C; Kinkel RP; Mainero C
    Ann Neurol; 2016 Nov; 80(5):776-790. PubMed ID: 27686563
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Covarying patterns of white matter lesions and cortical atrophy predict progression in early MS.
    Muthuraman M; Fleischer V; Kroth J; Ciolac D; Radetz A; Koirala N; Gonzalez-Escamilla G; Wiendl H; Meuth SG; Zipp F; Groppa S
    Neurol Neuroimmunol Neuroinflamm; 2020 May; 7(3):. PubMed ID: 32024782
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Functional Disability and Brain MRI Volumetry Results among Multiple Sclerosis Patients during 5-Year Follow-Up.
    Strautmane S; Balodis A; Teivane A; Grabovska D; Naudins E; Urbanovics D; Fisermans E; Mednieks J; Flintere-Flinte A; Priede Z; Millers A; Zolovs M
    Medicina (Kaunas); 2023 Jun; 59(6):. PubMed ID: 37374286
    [No Abstract]   [Full Text] [Related]  

  • 53. Clinical significance of cortical lesions in patients with multiple sclerosis: A neuropsychological and neuroimaging study.
    Matsushita F; Kida H; Tabei KI; Nakano C; Matsuura K; Ii Y; Sasaki R; Taniguchi A; Narita Y; Maeda M; Satoh M; Tomimoto H
    Brain Behav; 2018 Mar; 8(3):e00934. PubMed ID: 29541544
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The role of global and regional gray matter volume decrease in multiple sclerosis.
    Grothe M; Lotze M; Langner S; Dressel A
    J Neurol; 2016 Jun; 263(6):1137-45. PubMed ID: 27094570
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Evidence for relative cortical sparing in benign multiple sclerosis: a longitudinal magnetic resonance imaging study.
    Calabrese M; Filippi M; Rovaris M; Bernardi V; Atzori M; Mattisi I; Favaretto A; Grossi P; Barachino L; Rinaldi L; Romualdi C; Perini P; Gallo P
    Mult Scler; 2009 Jan; 15(1):36-41. PubMed ID: 18755823
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Regional cortical thinning in multiple sclerosis and its relation with cognitive impairment: A multicenter study.
    Tillema JM; Hulst HE; Rocca MA; Vrenken H; Steenwijk MD; Damjanovic D; Enzinger C; Ropele S; Tedeschi G; Gallo A; Ciccarelli O; Rovira A; Montalban X; de Stefano N; Stromillo ML; Filippi M; Barkhof F;
    Mult Scler; 2016 Jun; 22(7):901-9. PubMed ID: 26432859
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Association of Cortical Lesions With Regional Glutamate, GABA,
    Madsen MA; Považan M; Wiggermann V; Lundell H; Blinkenberg M; Romme Christensen J; Sellebjerg F; Siebner HR
    Neurology; 2024 Jul; 103(1):e209543. PubMed ID: 38870443
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Higher EBV response is associated with more severe gray matter and lesion pathology in relapsing multiple sclerosis patients: A case-controlled magnetization transfer ratio study.
    Jakimovski D; Ramanathan M; Weinstock-Guttman B; Bergsland N; Ramasamay DP; Carl E; Dwyer MG; Zivadinov R
    Mult Scler; 2020 Mar; 26(3):322-332. PubMed ID: 30755085
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinical and MRI efficacy of sc IFN β-1a tiw in patients with relapsing MS appearing to transition to secondary progressive MS: post hoc analyses of PRISMS and SPECTRIMS.
    Freedman MS; Brod S; Singer BA; Cohen BA; Hayward B; Dangond F; Coyle PK
    J Neurol; 2020 Jan; 267(1):64-75. PubMed ID: 31559532
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cortical dysfunction underlies disability in multiple sclerosis.
    Vucic S; Burke T; Lenton K; Ramanathan S; Gomes L; Yannikas C; Kiernan MC
    Mult Scler; 2012 Apr; 18(4):425-32. PubMed ID: 21965421
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.